[1]Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55(2):74-108.
[2]吴孟超,陈 汉,沈 锋.原发性肝癌的外科治疗—附5524例报告[J]. 中华外科杂志,2001, 39（1）：25-29.
[3]Spangenberg HC, Thimme R, Blum HE. Serum markers of hepatocellular carcinoma[J]. Semin Liver Dis,2006, 26(4):385-390.
[4]Libbrecht L, Severi T, Cassiman D, et al. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules[J]. Am J Surg Pathol, 2006, 30(11):1405-1411.
[5]Zinkin NT, Grall F, Bhaskar K,et al.Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease[J]. Clin Cancer Res, 2008, 14(2):470-477.
[6]Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells[J]. Nat Med, 2006, 12(4):410-416.
[7]Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation[J].Radiology, 2005, 234(3):961-967.
[8]Llovet JM. Updated treatment approach to hepatocellular carcinoma[J]. J Gastroenterol, 2005, 40(3):225-235.
[9]Huang GT, Lee PH, Tsang YM, et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study[J]. Ann Surg, 2005, 242(1):36-42.
[10]奚 韬,闫振林,王 葵,等. 术后经导管动脉化疗栓塞对不同病理特征肝癌的抗复发作用[J]. 中华外科杂志, 2007, 45（9）：587-590.
[11]沈 锋，吴孟超.肝癌切除术后的抗复发治疗[J]. 中华医学杂志，2005，41（2）：2886-2888.
[12]Liapi E, Geschwind JF. Transcatheter and ablative therapeutic approaches for solid malignancies[J]. J Clin Oncol, 2007, 25(8):978-986.
[13]Yamakado K, Nakatsuka A, Takaki H, et al. Early-stage hepatocellular carcinoma: radio-frequency ablation combined with chemoembolization versus hepatectomy[J]. Radiology, 2008, 247(1):260-266.
[14]Lau WY, Lai EC, Leung TW, et al. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival[J].Ann Surg,2008, 247(1):43-48.
[15]Pawlik TM, Izzo F, Cohen DS, et al.Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients[J].Ann Surg Oncol,2003, 10(9):1059-1069.
[16]Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials[J]. Aliment Pharmacol Ther, 2006, 23(11):1535-1547.
[17]Boige V, Barbare JC, Rosmorduc O,et al. Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations[J]. Gastroenterol Clin Biol, 2008, 32(1 Pt 1):3-7.